Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Neuro-oncology

Auditing Your Pathology Report & Biomarkers

At a Glance

Your glioblastoma pathology report relies on key biomarkers to guide treatment. The most critical is MGMT methylation, which predicts if standard chemotherapy will be effective. A complete report should also include an integrated diagnosis checking for TERT, EGFR, and IDH-wildtype status.

Your pathology report is the most important document in your medical file. It is the “blueprint” of your tumor, detailing its genetic makeup and how it is likely to behave. In the modern era of neuro-oncology (2024-2026), a complete report must include an Integrated Diagnosis—a summary that combines what the pathologist saw under the microscope with the results of deep molecular testing [1][2].

The MGMT “On/Off Switch”

The most critical biomarker for your treatment planning is MGMT promoter methylation. Think of the MGMT promoter as an “on/off switch” for a repair protein in the tumor cells [3].

  • Methylated (Switch is OFF): This is a positive finding. When the MGMT promoter is methylated, the tumor’s ability to repair itself is “turned off.” This makes the tumor much more sensitive to temozolomide (TMZ), the standard chemotherapy drug, because the drug can damage the cancer cells without them fixing themselves [4][5]. Patients with methylated tumors generally have a better response to treatment and a more favorable prognosis [6][7].
  • Unmethylated (Switch is ON): This means the tumor is actively producing a protein that repairs the damage caused by chemotherapy. While temozolomide is still often used, your doctor may discuss clinical trials or additional therapies because the tumor is more resistant to the standard drug [8][9].

Core Molecular Markers: TERT and EGFR

Beyond MGMT, two other markers are essential for confirming a glioblastoma diagnosis and understanding its aggressiveness:

  1. TERT Promoter Mutation: This mutation allows tumor cells to become “immortal” by constantly rebuilding their DNA [10]. In the absence of an IDH mutation, a TERT mutation is a primary marker that defines a tumor as a Grade 4 glioblastoma, even if it looks less aggressive under the microscope [11][12].
  2. EGFR Amplification: This occurs when the tumor has too many copies of the Epidermal Growth Factor Receptor, essentially giving it a “stuck gas pedal” for growth [13][14]. While it is a hallmark of glioblastoma, its presence is most useful for identifying eligibility for targeted clinical trials, such as those focusing on the EGFRvIII variant [15][16].

Your Pathology Completeness Checklist

To ensure your care team has all the information needed to build the best treatment plan, audit your report for these essential elements:

Element Why It Matters
IDH Status Must be IDH-wildtype for a true glioblastoma diagnosis [2].
MGMT Status Predicts if chemotherapy (temozolomide) will be effective [3].
WHO Grade Should be CNS WHO Grade 4 [1].
Molecular Upgrades If Grade 2/3, look for TERT, EGFR, or +7/-10 to confirm the grade [2].
H3 Status Must be H3-wildtype to rule out other rare midline tumors [17].
CDKN2A/B Loss of this gene can indicate a more aggressive clinical course (Note: This is primarily a crucial marker used to upgrade IDH-mutant tumors, but can still provide context on aggressive behavior in GBM) [1].

If any of these are missing, ask your doctor if “reflex” molecular testing has been ordered. These markers are not just numbers; they are the keys that your medical team uses to perform risk stratification—tailoring the intensity and type of your care to the specific risks posed by your tumor [18][19].

Common questions in this guide

What does an MGMT methylated result mean on my report?
A methylated MGMT promoter means the tumor's ability to repair itself is turned off. This usually makes the tumor much more sensitive to standard chemotherapy drugs like temozolomide, which can lead to a better treatment response.
What if my glioblastoma is MGMT unmethylated?
An unmethylated MGMT status means the tumor is actively producing a protein that repairs the damage caused by chemotherapy. While standard treatments are still used, you and your doctor may want to explore clinical trials or additional therapies.
Why is a TERT mutation important in glioblastoma?
A TERT promoter mutation allows tumor cells to constantly rebuild their DNA, making them essentially immortal. Its presence helps definitively classify a brain tumor as an aggressive Grade 4 glioblastoma, even if it looks less aggressive under the microscope.
What is an integrated diagnosis?
An integrated diagnosis combines what the pathologist sees under the microscope with the results of deep molecular and genetic testing. This provides the most complete and accurate blueprint of your tumor to help plan your care.
How does EGFR amplification affect my treatment options?
EGFR amplification acts like a stuck gas pedal that drives tumor growth. Knowing if your tumor has this marker, especially the EGFRvIII variant, helps your care team determine if you are a candidate for specific targeted clinical trials.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my MGMT status 'methylated' or 'unmethylated,' and how does that specifically affect my chemotherapy plan?
  2. 2.Does my tumor have the EGFRvIII mutation, and if so, are there targeted clinical trials available for me?
  3. 3.Was the testing for TERT, EGFR, and chromosome 7/10 performed using the latest WHO standards?
  4. 4.My report says 'Integrated Diagnosis'—can you walk me through how the molecular findings and the cell appearance were combined to reach this conclusion?
  5. 5.If my tumor is MGMT-unmethylated, are we considering any additional treatments beyond temozolomide?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.

    Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN

    JAMA oncology 2022; (8(10)):1493-1501 doi:10.1001/jamaoncol.2022.2844.

    PMID: 36006639
  2. 2

    Molecular GBM versus Histopathological GBM: Radiology-Pathology-Genetic Correlation and the New WHO 2021 Definition of Glioblastoma.

    Agarwal A, Edgar MA, Desai A, et al.

    AJNR. American journal of neuroradiology 2024; (45(8)):1006-1012 doi:10.3174/ajnr.A8225.

    PMID: 38438167
  3. 3

    Prognostic and Predictive Biomarkers in Gliomas.

    Śledzińska P, Bebyn MG, Furtak J, et al.

    International journal of molecular sciences 2021; (22(19)) doi:10.3390/ijms221910373.

    PMID: 34638714
  4. 4

    Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.

    Li H, Wu Y, Chen Y, et al.

    Acta neuropathologica communications 2025; (13(1)):126 doi:10.1186/s40478-025-02046-4.

    PMID: 40468460
  5. 5

    Epigenetic modification and characterization of the MGMT promoter region using CRISPRoff in glioblastoma cells.

    Weber R, Weller M, Reifenberger G, Vasella F

    Frontiers in oncology 2024; (14()):1342114 doi:10.3389/fonc.2024.1342114.

    PMID: 38357209
  6. 6

    MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study.

    Szylberg M, Sokal P, Śledzińska P, et al.

    Biomedicines 2022; (10(8)) doi:10.3390/biomedicines10082030.

    PMID: 36009577
  7. 7

    The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.

    Kurdi M, Shafique Butt N, Baeesa S, et al.

    Pathology oncology research : POR 2021; (27()):1609778 doi:10.3389/pore.2021.1609778.

    PMID: 34257620
  8. 8

    Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.

    Xi YB, Guo F, Xu ZL, et al.

    Journal of magnetic resonance imaging : JMRI 2018; (47(5)):1380-1387 doi:10.1002/jmri.25860.

    PMID: 28926163
  9. 9

    Proteomic and metabolomic analyses illustrate the mechanisms of expression of the O6 -methylguanine-DNA methyltransferase gene in glioblastoma.

    Chen X, Sun J, Li Y, et al.

    CNS neuroscience & therapeutics 2024; (30(2)):e14415 doi:10.1111/cns.14415.

    PMID: 37641495
  10. 10

    Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme.

    Jeong DE, Woo SR, Nam H, et al.

    Oncology letters 2017; (14(6)):8213-8219 doi:10.3892/ol.2017.7196.

    PMID: 29344264
  11. 11

    Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?

    Teske N, Karschnia P, Weller J, et al.

    Journal of neuro-oncology 2022; (156(2)):317-327 doi:10.1007/s11060-021-03912-6.

    PMID: 34902093
  12. 12

    Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers.

    Varachev V, Susova O, Mitrofanov A, et al.

    International journal of molecular sciences 2024; (25(23)) doi:10.3390/ijms252313004.

    PMID: 39684714
  13. 13

    The Prognostic Significance of Epidermal Growth Factor Receptor Amplification and Epidermal Growth Factor Receptor Variant III Mutation in Glioblastoma: A Systematic Review and Meta-Analysis with Implications for Targeted Therapy.

    Zhu F, Qiu J, Ye H, et al.

    International journal of molecular sciences 2025; (26(8)) doi:10.3390/ijms26083539.

    PMID: 40331985
  14. 14

    Glioblastoma at the crossroads: current understanding and future therapeutic horizons.

    Singh S, Dey D, Barik D, et al.

    Signal transduction and targeted therapy 2025; (10(1)):213 doi:10.1038/s41392-025-02299-4.

    PMID: 40628732
  15. 15

    Clinical progress in the development of CAR T cells to treat malignant glioma.

    Grewal EP, Nahed BV, Carter BS, et al.

    Journal of neuro-oncology 2025; (171(3)):571-579 doi:10.1007/s11060-024-04909-7.

    PMID: 39695004
  16. 16

    Enhanced Detection of EGFRvIII in Tumors: A Comparative Study of Split Read- and Read Depth-Based DNA Sequencing Approaches.

    Chen N, Feng J, Wan D, et al.

    The Journal of molecular diagnostics : JMD 2025; doi:10.1016/j.jmoldx.2025.11.002.

    PMID: 41320124
  17. 17

    The Role of Ketone Bodies in Treatment Individualization of Glioblastoma Patients.

    Tamas C, Tamas F, Kovecsi A, et al.

    Brain sciences 2023; (13(9)) doi:10.3390/brainsci13091307.

    PMID: 37759908
  18. 18

    Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study.

    Dipasquale A, Franceschi E, Giordano L, et al.

    ESMO open 2024; (9(6)):103485 doi:10.1016/j.esmoop.2024.103485.

    PMID: 38833969
  19. 19

    Pre-operative MRI radiomics model non-invasively predicts key genomic markers and survival in glioblastoma patients.

    Pease M, Gersey ZC, Ak M, et al.

    Journal of neuro-oncology 2022; (160(1)):253-263 doi:10.1007/s11060-022-04150-0.

    PMID: 36239836

This guide explains glioblastoma pathology terms for educational purposes only. Always consult your neuro-oncologist or pathologist to accurately interpret your specific biomarker results and diagnosis.

Get notified when new evidence is published on Glioblastoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.